Pharmamarketeer

Sanofi announces positive results from phase 3 trial for Toujeo in children and adolescents with type 1 diabetes

Children and adolescents (aged 6 to 17 years) living with type 1 diabetes achieved comparable reduction in average blood sugar (HbA1c) and similar risk of low blood sugar events with Toujeo (insulin glargine 300

Medhc-fases-banner
Advertentie(s)